Disc Medicine, Inc.

NasdaqGM:IRON Stock Report

Market Cap: US$1.6b

Disc Medicine Management

Management criteria checks 1/4

Disc Medicine's CEO is John Quisel, appointed in Feb 2020, has a tenure of 5.25 years. total yearly compensation is $9.07M, comprised of 7.1% salary and 92.9% bonuses, including company stock and options. directly owns 0.097% of the company’s shares, worth $1.59M. The average tenure of the management team and the board of directors is 1.8 years and 4.6 years respectively.

Key information

John Quisel

Chief executive officer

US$9.1m

Total compensation

CEO salary percentage7.11%
CEO tenure5.3yrs
CEO ownership0.1%
Management average tenure1.8yrs
Board average tenure4.6yrs

Recent management updates

Recent updates

Disc Medicine: Potential Promise Amid Uncertainty

Jan 21

Disc Medicine, Inc. (NASDAQ:IRON) Shares Could Be 29% Below Their Intrinsic Value Estimate

Jan 02
Disc Medicine, Inc. (NASDAQ:IRON) Shares Could Be 29% Below Their Intrinsic Value Estimate

Disc Medicine: Achieving Functional Endpoint More Important

Oct 06

Disc Medicine (NASDAQ:IRON) Is In A Good Position To Deliver On Growth Plans

Aug 13
Disc Medicine (NASDAQ:IRON) Is In A Good Position To Deliver On Growth Plans

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Jun 14

Disc Medicine: What's Behind The Huge Rally

Jan 31

CEO Compensation Analysis

How has John Quisel's remuneration changed compared to Disc Medicine's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$116m

Dec 31 2024US$9mUS$645k

-US$109m

Sep 30 2024n/an/a

-US$103m

Jun 30 2024n/an/a

-US$91m

Mar 31 2024n/an/a

-US$81m

Dec 31 2023US$909kUS$562k

-US$76m

Sep 30 2023n/an/a

-US$64m

Jun 30 2023n/an/a

-US$66m

Mar 31 2023n/an/a

-US$60m

Dec 31 2022US$2mUS$476k

-US$47m

Sep 30 2022n/an/a

-US$44m

Jun 30 2022n/an/a

-US$37m

Mar 31 2022n/an/a

-US$37m

Dec 31 2021US$2mUS$455k

-US$36m

Dec 31 2020US$820kUS$373k

-US$21m

Compensation vs Market: John's total compensation ($USD9.07M) is above average for companies of similar size in the US market ($USD6.15M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Quisel (53 yo)

5.3yrs

Tenure

US$9,065,924

Compensation

Dr. John D. Quisel, J.D., Ph D., Esq., serves as Independent Director of Gossamer Bio, Inc. since November 2023. He serves as Chief Executive Officer of Disc Medicine, Inc. since February 25, 2020 and serv...

Leadership Team

NamePositionTenureCompensationOwnership
Donald Nicholson
Executive Chairman6.1yrsUS$446.68k0.044%
$ 722.0k
John Quisel
CEO, President & Director5.3yrsUS$9.07m0.097%
$ 1.6m
Jean Franchi
Chief Financial Officer1.3yrsUS$5.30m0.017%
$ 283.9k
Jonathan Yu
Chief Opearating Officer1.3yrsUS$2.94m0.0085%
$ 138.0k
William Savage
Chief Medical Officer3.8yrsUS$3.05m0.19%
$ 3.1m
Pamela Stephenson
Chief Commercial Officer1.3yrsUS$5.21m0.017%
$ 283.9k
Brian MacDonald
Founder & Chair of Scientific Advisory Board7.6yrsUS$88.54kno data
Rahul Kaushik
Chief Technical Officerless than a yearno datano data
Rahul Khara
Chief Legal Officer & Secretary3.4yrsno data0.11%
$ 1.8m
Srikanth Venkatraman
Senior VP & Head of Chemistryno datano datano data
Hua Yang
Senior Vice President & Head of Early Development and Clinical Pharmacology2.3yrsno datano data
Sonia Razzetti
Senior Vice President of Quality1.3yrsno datano data

1.8yrs

Average Tenure

54.5yo

Average Age

Experienced Management: IRON's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Donald Nicholson
Executive Chairman6.1yrsUS$446.68k0.044%
$ 722.0k
John Quisel
CEO, President & Director5.3yrsUS$9.07m0.097%
$ 1.6m
Brian MacDonald
Founder & Chair of Scientific Advisory Board1.4yrsUS$88.54kno data
Kevin Bitterman
Independent Director7.5yrsUS$335.68k0%
$ 0
Tomas Ganz
Member of Scientific Advisory Board4.6yrsno datano data
Mona Ashiya
Independent Director3.7yrsUS$331.68k0%
$ 0
Liam Ratcliffe
Independent Director5.7yrsUS$334.18k0%
$ 0
Elizabeta Nemeth
Member of Scientific Advisory Board4.6yrsno datano data
Mark Chin
Independent Director3.7yrsUS$330.18k0%
$ 0
William White
Independent Director4.4yrsUS$337.68k0%
$ 0
Stefano Rivella
Member of Scientific Advisory Boardno datano datano data
Mark Fleming
Member of Scientific Advisory Boardno datano datano data

4.6yrs

Average Tenure

53yo

Average Age

Experienced Board: IRON's board of directors are considered experienced (4.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/16 01:36
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Disc Medicine, Inc. is covered by 13 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Evan SeigermanBMO Capital Markets Equity Research
Kristen KluskaCantor Fitzgerald & Co.
Douglas TsaoH.C. Wainwright & Co.